Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
Arcutis announced that ZORYVE (roflumilast) cream received a strong recommendation with high certainty of clinical evidence in the American Academy of Dermatology's first-ever pediatric atopic dermatitis guidelines. The guidelines recommend ZORYVE cream 0.05% for children aged 2-5 years and ZORYVE cream 0.15% for children aged 6 years and older with mild to moderate atopic dermatitis.
Key figures
- Adult atopic dermatitis patients us
- 16.5 million
- Pediatric atopic dermatitis patients us
- 9.6 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.